Merck, a leading science and technology company, held its 28th Annual General Meeting virtually today. All of the resolutions on the agenda were approved, ...
The transaction provides Abbott with a complementary solution for treating vascular disease. CSI's leading atherectomy system prepares vessels for angiopla...
The items on the agenda of the ordinary and extraordinary general shareholders' meetings include the proposed approval of a number of resolutions relating ...
Furthermore, the Company received notice from the Gardiner Sponsor that the Gardiner Sponsor intends to deposit funds into the trust account under the Trus...
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) (“Vallon” or the “Company”) today announced that its stockholders have approved Proposa...
The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its res...
Co-founded by acclaimed oncologist Dennis Slamon, M.D., Ph.D., of University of California at Los Angeles (UCLA) and entrepreneur and CEO David Licata, a...
PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences&rs...
The loan carries 10% simple interest, may be prepaid without penalty, is extendable for an additional six months and includes warrants to purchase 390,000 ...
On 23 January 2023, the acceptance period during which DSM Shareholders can tender their DSM Ordinary Shares into the Exchange Offer was extended as not al...
The proceeds from this Series A extension round are being utilized to advance the development of Trobix Bio's products and cutting-edge proprietary platfor...
The EIC investment was made through its Accelerator Fund, designed to support small and medium enterprises (SMEs), in particular start-ups and spin-out com...
"We are running a comprehensive development program for tarcocimab tedromer with topline data from four Phase 3 studies planned for 2023: two for the long-...
Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian Healthtech company, announce...
© 2025 Biopharma Boardroom. All Rights Reserved.
